Evidence map›Paper›PMID 42396325›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Automated Text Message Outreach to Increase Diabetes Screening: A Pragmatic Randomized Trial.

Hayoung Jeong, Leeor Hershkovich, Victoria Glunt, Logan White, Karnika Singh, Matthew J Crowley, Benjamin A Goldstein, Anastasia-Stefania Alexopoulos, Jessilyn Dunn

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hayoung JeongDepartment of Biomedical Engineering, Duke University, Durham, NC.ORCID 0000-0002-0359-8218
Leeor HershkovichDepartment of Biomedical Engineering, Duke University, Durham, NC.ORCID 0000-0001-7361-4765
Victoria GluntDepartment of Medicine, Duke University Health System, Durham, NC.
Logan WhiteDuke Health Technology Solutions, Durham, NC.
Karnika SinghDepartment of Biomedical Engineering, Duke University, Durham, NC.ORCID 0000-0003-1181-2090
Matthew J CrowleyDepartment of Medicine, Duke University Health System, Durham, NC.ORCID 0000-0002-6205-4536
Benjamin A GoldsteinDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC.ORCID 0000-0001-5261-3632
Anastasia-Stefania AlexopoulosDivision of Endocrinology, Nutrition and Metabolism, Department of Medicine, Duke University, Durham, NC.ORCID 0000-0002-0690-1526
Jessilyn DunnDepartment of Biomedical Engineering, Duke University, Durham, NC.ORCID 0000-0002-3241-8183

Funding

EXpanding Technology-Enabled, Nurse-Delivered Chronic Disease Care (EXTEND)R01NR019594 · NINR · DUKE UNIVERSITY · PI CROWLEY, MATTHEW J., SHAW, RYAN JEFFREY · 2021 to 2025
$3.4M
Mobile technologies to screen for prediabetes and type 2 diabetes in asymptomatic adultsR01DK133531 · NIDDK · DUKE UNIVERSITY · PI JESSILYN P DUNN · 2023 to 2026
$2.5M
Mechanistic Insights into Health Disparities: Leveraging Longitudinal Wearable Data to Assess the Impact of Built Environment on Physical Activity and Health OutcomesF31HL179990 · NHLBI · DUKE UNIVERSITY · PI Hayoung Jeong · 2025 to 2026
$86k
NHLBI NIH HHS F31 HL179990NIDDK NIH HHS R01 DK133531NINR NIH HHS R01 NR019594
6 · The paper itself

Abstract

Background: Despite evidence that early intervention can prevent or delay progression to type 2 diabetes, more than 80% of individuals with prediabetes in the United States remain undiagnosed, underscoring the need for scalable strategies to increase uptake. In this study, we evaluated whether a single text message could increase completion of HbA1c-based diabetes screening in routine clinical practice. Methods: We conducted a pragmatic randomized controlled trial within Duke University Health System (DUHS). Patients aged 35 years or older who met American Diabetes Association 2022 screening criteria, had no previous diagnosis of diabetes, had not undergone HbA1c testing within the preceding 3 years, and had opted to receive text messages from DUHS were randomly assigned to receive either a single text message encouraging guideline-based diabetes screening and discussion with a primary care provider (intervention group; n=55,494) or usual care (control group; n=5,748). The primary outcome was HbA1c test completion within 24 weeks following message delivery (or no message for controls), analyzed using a Cox proportional hazards model stratified by wave. Secondary outcomes included piecewise hazard ratios for early (weeks 1-4), mid (weeks 5-12), and late (weeks 13-24) intervals and the between-group difference in cumulative testing rate. Findings: Text message outreach significantly increased HbA1c test completion over 24 weeks (HR, 1.18 [95% CI, 1.07-1.03]) with the strongest effect in the first four weeks (HR, 1.48 [95% CI, 1.18-1.86]). By the end of the 24-week observation period, cumulative testing reached 9.14% in the messaged group vs 7.83% in controls (between-group difference, 1.31% [95% CI, 0.59-2.07]), corresponding to one additional HbA1c test per 76 messages delivered ($0.51 in messaging costs per additional HbA1c test performed). Rates of prediabetes and diabetes among those screened were similar between groups, indicating no selection bias of higher-risk patients. One additional dysglycemia case was identified per 213 messages sent ($1.43 per case detected). Interpretation: A single automated text message can increase diabetes screening completion at low marginal cost without selectively engaging higher-risk patients. This low-cost, highly scalable approach could be used to narrow the gap between current and recommended diabetes screening.

Identifiers

PMID42396325
PMCPMC13321112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.